Prestimulation with Recombinant Human Thyrotropin (rhTSH) Improves the Long-Term Outcome of Radioiodine Therapy for Multinodular Nontoxic Goiter | Zendy

Søren Fast | Zendy; Viveque Egsgaard Nielsen | Zendy; Peter Grupe | Zendy; Henrik Boel-Jørgensen | Zendy; Lars Bastholt | Zendy; P. B. Andersen | Zendy; Steen Joop Bonnema | Zendy; László Hegedűs | Zendy

Open Access

Prestimulation with Recombinant Human Thyrotropin (rhTSH) Improves the Long-Term Outcome of Radioiodine Therapy for Multinodular Nontoxic Goiter

Author(s) -

Søren Fast,

Viveque Egsgaard Nielsen,

Peter Grupe,

Henrik Boel-Jørgensen,

Lars Bastholt,

P. B. Andersen,

Steen Joop Bonnema,

László Hegedűs

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-3335

Subject(s) - multinodular goiter , radioiodine therapy , medicine , recombinant dna , term (time) , goiter , endocrinology , oncology , cancer , thyroid , thyroid cancer , biology , genetics , physics , quantum mechanics , gene

The objective of the study was to evaluate the long-term outcome of recombinant human TSH (rhTSH)-augmented radioiodine ((131)I) therapy for benign multinodular nontoxic goiter.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research